NOVAVAX INC
No SEC Form 4 filings for $NVAX in the last 30 days.
See all $NVAX insider activity →Shah Capital, Novavax's second-largest shareholder, is stepping back from its activist role after restructuring into a family office. The firm filed to withdraw its registration as an investment adviser and sold 2.87 million shares at $11.35 each on October 5. Himanshu Shah, the founder, now holds 10.66 million shares, about 6.46% of Novavax.
Novavax (NVAX) fell 12% to $11.23, Moderna (MRNA) dropped 10% to $212.80, while Pfizer (PFE) rose 0.5% to $29.59. Citi maintained a Sell rating on NVAX but raised its price target. NVAX's revenue depends on Sanofi's (SNY) Nuvaxovid sales and milestones, creating uncertainty.
Novavax (NVAX) stock fell 10.5% to $11.475 after Citigroup reiterated a Sell rating with a $8 price target, 38% below its 52-week high. High short interest and a bearish note from Bank of America also contributed to the decline. The broader market's negative tone added to the pressure.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NVAX (NOVAVAX INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 3 bearish.
Recent NVAX coverage spans financial news, market movers and earnings.
Activist exit and sizable share sale may weigh on NVAX price.
Near-term downside risk for NVAX as investors reprice uncertainty around Sanofi-driven royalties and milestone timing.
The downgrade and low price targets increase downside pressure on NVAX.
Street PTs moved higher and consensus tilted more bullish, which can support near-term sentiment but is not a new fundamental catalyst by itself.
Investor optimism from biotech news.
AlphAI scores every news story that mentions NVAX with an AI model for sentiment and relevance, and aggregates insider trades from NOVAVAX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Shah Capital, Novavax's second-largest shareholder, is stepping back from its activist role after restructuring into a family office. The firm filed to withdraw its registration as an investment adviser and sold 2.87 million shares at $11.35 each on October 5. Himanshu Shah, the founder, now holds 10.66 million shares, about 6.46% of Novavax.
1 min readNovavax (NVAX) fell 12% to $11.23, Moderna (MRNA) dropped 10% to $212.80, while Pfizer (PFE) rose 0.5% to $29.59. Citi maintained a Sell rating on NVAX but raised its price target. NVAX's revenue depends on Sanofi's (SNY) Nuvaxovid sales and milestones, creating uncertainty.
5 min readNovavax (NVAX) stock fell 10.5% to $11.475 after Citigroup reiterated a Sell rating with a $8 price target, 38% below its 52-week high. High short interest and a bearish note from Bank of America also contributed to the decline. The broader market's negative tone added to the pressure.
2 min readNovavax, Inc.'s average stock price target increased from $14.86 to $15, with estimates ranging from $8 to $25, implying a 19% upside from the Oct. 14 close. Analysts' consensus rating shifted to 'Buy' with 4 Buys, 1 Hold, and 2 Sells.
1 min readU.S. stocks rose on Friday, led by tech, with all three major indexes gaining weekly. The Dow added 423 points, S&P 500 up 46, Nasdaq up 173. OpenAI's revenue miss caused a tech selloff, but rebound followed. Nvidia, Micron, and others recovered. Trump announced a Russia diesel deal, pushing indexes higher. Treasury yields remain elevated. Apple shares fell 1.1% on production cuts. Moderna and Novavax surged on vaccine news. Telecoms dropped on SpaceX's spectrum acquisition.
3 min readA new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.
2 min readAnalysts raised Novavax's (NVAX) average price target to $14.86, up from $14.71, with estimates ranging from $7 to $25. The new target suggests a 35% upside from the Oct. 8 closing price. The consensus rating is now 'Buy' among 7 analysts, with 4 'Buys', 1 'Hold', and 2 'Sells'.
1 min readNovavax (NVAX) shares rose 13.7% as investors focused on its partnership with Sanofi, including a potential $125M milestone payment. The surge follows regulatory approvals in Europe for Sanofi's COVID-Influenza vaccine trial. NVAX's royalty model and analyst price target ($14.00) also support the rally, while broader market gains provide additional tailwinds.
2 min readMyriad Genetics (MYGN) reported Q2 revenue of $190.7M, down 10.5% YoY, missing estimates. It lowered full-year guidance, causing its stock to drop 20.7%. Amgen (AMGN) reported $10.05B in Q2 revenue, up 9.5% YoY, beating estimates. Novavax (NVAX) reported $56.7M in Q2 revenue, down 76.3% YoY, but beat EPS estimates. Both AMGN and NVAX stocks rose post-earnings.
2 min readSimply Wall St analyzes Novavax (NVAX), highlighting potential rewards and risks for investors. The article suggests NVAX could be worth over 4x its current price and provides a comprehensive financial health analysis. It also mentions other AI, robotics, and quantum computing stocks as potential investment opportunities.
2 min read
